Search the Newsreel

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

Pomerantz LLP is investigating potential claims on behalf of investors of AstraZeneca PLC (NYSE: AZN) following a significant drop in its stock price. This investigation comes after AstraZeneca disclosed that its late-stage Phase-3 CARDIO-TTransform trial for Wainua, an amyloid cardiomyopathy treatment, failed to meet …

AstraZeneca Stock Leads 3 Cash Flow Picks Worth Watching In Europe

Deal or No Deal, AstraZeneca Stock Is a Bargain

AstraZeneca's stock has become a potential bargain after recent investor concerns over a rumored megamerger with Bristol-Myers Squibb. Despite CEO Pascal Soriot's reputation for fostering growth through internal R&D and smaller, targeted acquisitions, the company's shares are down over 10% for the year and …

AZN rebounds after report dismisses AstraZeneca-Bristol Myers merger speculation

Astra Zeneca logo on building ©Adobe Stock Images AstraZeneca (NASDAQ:AZN) shares climbed around 6% on Wednesday after Reuters reported that there are "no discussions" between the company and Bristol Myers Squibb (NYSE:BMY) regarding a potential merger, contradicting recent speculation that had unsettled investors. The …

Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

By Maggie Fick and Sabrina Valle Aug 5 (Reuters) - There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a ‌potential deal, a senior source close to the matter told ‌Reuters on Wednesday, quashing the prospect of a mooted mega merger …

Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls

Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top …

AZN spikes 6% after report it denies AstraZeneca-BMS merger talks

Investing.com - AstraZeneca shares surged approximately 6% on Wednesday after a senior source told Reuters there are "no discussions" between AstraZeneca and Bristol Myers Squibb over a potential deal, flatly quashing reports of a merger that would have created a pharmaceutical giant worth nearly …

AstraZeneca climbs Wednesday, outperforms market

Shares of AstraZeneca PLC (AZN) rose 2.52% to £120.36 on Wednesday, outperforming the FTSE 100 Index, which increased by 0.08%. The company's stock closed 23.49% below its 52-week high of £157.32.

AstraZeneca Stock Drops 7% as Merger Talks With Bristol Myers Squibb Surface

AstraZeneca and Bristol Myers Squibb never held merger discussions and are not in talks now, a senior source close to the matter told Reuters on Wednesday. "There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there …

AstraZeneca PLC Stock (AZN) Moved Up by 4.30% on Aug 5: A Full Analysis

Bristol Myers Squibb Potential Deal With AstraZeneca Seen Unlikely as Shareholder Views Diverge, RBC Says

Bristol Myers Squibb's (BMY) reported merger discussions with AstraZeneca (AZN) will unlikely result PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? …

Brokers split on AstraZeneca merger talk as shares recover some ground

Brokers split on AstraZeneca merger talk as shares recover some ground Proactive uses images sourced from Shutterstock Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank …

AstraZeneca (LSE:AZN) Is In Merger Talks With Bristol Myers For $400 Billion

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca (LSE:AZN) is reported to be in advanced merger talks with Bristol Myers Squibb. The potential deal could create a combined pharmaceutical company valued at about US$400b. …

AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).SOPHiA GENETICS Logo This multi-year collaboration agreement will advance …

My AstraZeneca shares just crashed 9.7%! Here’s why I’m NOT selling

AstraZeneca shares dropped significantly due to rumors of a potential mega-merger with Bristol Myers Squibb and a failed late-stage trial for its heart disease program, Wainua. Despite these setbacks, an investor is not selling, viewing the decline as a market overreaction rather than a …

More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading

Bristol-Myers Squibb, AstraZeneca deal talks remain active - report

A recent report indicates that deal talks between AstraZeneca and Bristol-Myers Squibb are still ongoing. Following this news, Bristol-Myers Squibb's shares saw a slight increase, while AstraZeneca's shares experienced a minor decline. This update follows an earlier Financial Times report about potential acquisition discussions.

AstraZeneca and Bristol-Myers Squibb: Megamerger Reports Leave Us Scratching Our Heads

Morningstar reports on the potential megamerger between Bristol-Myers Squibb and AstraZeneca, noting that such large acquisitions are rare in biopharma. While the deal could combine complementary patent portfolios and pipeline assets, concerns exist regarding integration challenges and regulatory hurdles due to overlapping oncology focuses. …

AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company developing cancer, rare-disease and other medicines, plunged approximately 7.7% in Monday's U.S. regular-session trading as investors assessed reported merger discussions with Bristol Myers Squibb (NYSE:BMY), a U.S. biopharmaceutical company. A combination could …

The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Bristol-Myers Squibb (BMY) shares opened higher on Monday following reports that the U.S. pharma giant held preliminary merger talks with UK rival AstraZeneca (AZN). If finalized, this reported transaction would create the world's largest drugmaker (by revenue) with a market cap approaching $400 billion. …

Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”

Quick Read BMY's existing $2B cost-savings program and discounted forward P/E of ~10 make it an attractive AZN acquisition target, Holz argues. Eli Lilly's $1 trillion market cap dwarfs all pharma rivals, pushing companies like Merck to pursue deals ahead of looming patent cliffs. …

AstraZeneca Investors See Little Logic in Bristol Tie-Up

AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. View Comments

Stocks mixed as AstraZeneca merger talk dents FTSE 100

The FTSE 100 underperformed European peers on Monday as heavy falls in AstraZeneca outweighed more optimistic noises in the Middle East. The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70. The FTSE 250 ended up 249.75 points, 1.0%, at 24,224.77, while the …

AstraZeneca shares slump after $400bn BMS merger rumours

Shares in AstraZeneca dropped by nearly 3% at market open after a report that the drugmaker is in talks with oncology rival Bristol Myers Squibb (BMS) regarding a mega-merger deal. According to the Financial Times (FT), which first reported the discussions, a tie-up would …

AstraZeneca Nosedives On A Rumored Megamerger; Is $160 Billion Enough?

AstraZeneca stock took a nosedive Monday amid reports it's mulling a megamerger with Bristol Myers Squibb. Continue Reading

Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?

Investing.com - AstraZeneca are trading roughly 9% lower on Monday after the Financial Times first reported, followed by Reuters and Bloomberg, that the British drugmaker held preliminary discussions with Bristol Myers Squibb about a combination that would create a nearly $400 billion pharmaceutical giant. …

Top Midday Stories: Amazon Market Cap Hits $3 Trillion; AstraZeneca, Bristol Myers Squibb Reportedly Discuss $400 Billion Combination

All three major US stock indexes were up in late-morning trading Monday after President Donald Trump PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Astra Buying Bristol Makes No Sense, Fazeli Says

AstraZeneca shares plunged Monday on news that the drugmaker was exploring an acquisition of Bristol Meyers Squibb. A deal would create one of the world's biggest drugmakers. Sam Fazeli of Bloomberg Intelligence says a takeover would make no sense. View Comments

European Stocks Close Mostly Higher in Monday Trading; AstraZeneca Reportedly in Merger Talks With Bristol Myers

European stock markets closed mostly higher in Monday trading as the Stoxx Europe gained 0.4%, Germa PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca

AstraZeneca completed a direct listing on the New York Stock Exchange back in February, after delisting its American Depositary Receipts from the Nasdaq Credit: Michael Nagle / Bloomberg via Getty Images Key Takeaways Bristol Myers Squibb shares rose Monday following reports of merger talks …

AstraZeneca Stock Nosedives On Mega-Merger Rumor

AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb. Continue Reading

AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point

AIM ImmunoTech Inc. Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 OCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the final subject …

AstraZeneca slides Monday, underperforms market

AstraZeneca PLC (AZN) shares fell by 8.96% to £115.00 on Monday, underperforming the broader market as the FTSE 100 Index also saw a slight decline. This drop left AstraZeneca's stock 26.90% below its 52-week high achieved in February.

AstraZeneca Weighs a Deal Its CEO Said It Didn't Need

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the UK drugmaker and the country's second most valuable listed company, fell 6.27% in London after news that it has held talks with Bristol Myers Squibb (NYSE:BMY) about a combination valued near $400 billion, according to …

Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca

The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion. Continue Reading